title: Public-Private Partnerships in Lead Discovery: Overview and Case Studies.
abstract: The pharmaceutical industry is faced with significant challenges in its efforts to discover new drugs that address unmet medical needs. Safety concerns and lack of efficacy are the two main technical reasons for attrition. Improved early research tools including predictive in silico, in vitro, and in vivo models, as well as a deeper understanding of the disease biology, therefore have the potential to improve success rates. The combination of internal activities with external collaborations in line with the interests and needs of all partners is a successful approach to foster innovation and to meet the challenges. Collaboration can take place in different ways, depending on the requirements of the participants. In this review, the value of public-private partnership approaches will be discussed, using examples from the Innovative Medicines Initiative (IMI). These examples describe consortia approaches to develop tools and processes for improving target identification and validation, as well as lead identification and optimization. The project "Kinetics for Drug Discovery" (K4DD), focusing on the adoption of drug-target binding kinetics analysis in the drug discovery decision-making process, is described in more detail.
authors.affiliation: Bayer Pharma AG, Berlin, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Gottwald
authors.affiliation: Bayer Pharma AG, Berlin, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Becker
authors.affiliation: Bayer Pharma AG, Berlin, Germany.
authors.forename: Inke
authors.initials: I
authors.lastname: Bahr
authors.affiliation: Bayer Pharma AG, Berlin, Germany. anke.mueller-fahrnow@bayer.com.
authors.forename: Anke
authors.initials: A
authors.lastname: Mueller-Fahrnow
mesh_terms: D055808:Drug Discovery / Q000458:organization & administration*; D004345:Drug Industry / Q000379:methods; D006801:Humans; D055818:Public-Private Sector Partnerships
keywords: Assay; Inhibitors; Rational drug design